Clinical trials: Hemostatic Agents
B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
This phase I trial studies the side effects, best way to give, and the best dose of alvocidib when given together with fludarabine phosphate and rituximab in treating patients with previously untreated or relapsed…
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma
- Trial name
- NCT00058227
- Testing
- alvocidib, fludarabine phosphate, rituximab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
The purpose of this study is to describe the safety and effect of ATN-224 in combination with bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory to bortezomib.
- Trial name
- NCT00352742
- Testing
- ATN-224 + bortezomib
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Attenuon
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Anorexia Nervosa, Thrombosis
Thromboembolism in Anorexia Nervosa
BACKGROUND: Sudden death due to thromboembolic (TE) events in patients with anorexia nervosa (AN) is well known. However, the incidence of TE events and the hemostatic balance in patients with AN are sparsely investigated.
- Conditions
- Anorexia Nervosa, Thrombosis, Thromboembolism
- Trial name
- TEAN (NCT05575466)
- Testing
- Blood samples, Questionnaires
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Multiple Myeloma, Plasma Cell Leukemia
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
The primary objectives of this study are to: To determine the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen.
- Trial name
- NCT00307086
- Testing
- Bortezomib, Melphalan, PBSCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Telemonitoring Among Patients With Multiple Myeloma
A two-arm open-label parallel-group randomized controlled trial will be conducted to compare the telemonitoring (MM e-coach) with standard MM care.
- Trial name
- ITUMM (NCT05964270)
- Testing
- e-coach multipel myeloma (MM)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Isala
Multiple Myeloma, AL Amyloidosis
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL).
- Trial name
- NCT07638683
- Testing
- Teclistamab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma
Microdose Study of Melphalan, Bortezomib and Dexamethasone
The purpose of the study is to identify specific genes that are up- or downregulated in multiple myeloma patients who receive a microdose of either Melphalan (Alkeran®), Bortezomib (Velcade®) or Dexamethasone (Dexaven®).
- Trial name
- Phase-0-MM (NCT02109861)
- Testing
- Melphalan, Bortezomib, Dexamethasone
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Henrik Gregersen
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00008242
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
The present protocol aims to test, whether an approach using (i) a reduced-toxicity TBF followed by a (ii) Daratumumab maintenance and (iii) prophylactic infusion of donor lymphocytes (pDLI), will be able to improve…
- Trial name
- DARALLO (NCT04024384)
- Testing
- Daratumumab
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Disorders of Coagulation
Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery
The purpose of this study is to investigate the effect of thin fluid with starch versus thin fluid without starch on coagulation in elective surgery when the patient is normovolæmic during operation.
- Trial name
- NCT02009033
- Testing
- Lactated Ringer, Hydroxyethylstarch
- Volunteers
- 40 people
- Sponsor
- K. C. Rasmussen
Hyperviscosity Syndrome, Waldenstrom Macroglobulinemia
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood.
- Trial name
- SLPRaresHvisc (NCT04898647)
- Testing
- fundoscopic picture, blood sample, bone marrow sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
This study will evaluate the safety and the efficacy of the MLN-DEXAMETHASONE, MLN-DEXAMETHASONE-CYCLOPHOSPHAMIDE, or MLN- THALIDOMIDE-DEXAMETHASONE induction combinations, followed by MLN maintenance in newly diagnosed elderly…
- Trial name
- NCT02586038
- Testing
- MLN9708, Dexamethasone, Cyclophosphamide
- Where
- Italy
- Volunteers
- 175 people
- Sponsor
- Mario Boccadoro
Gastro Intestinal Bleeding, Polyps
Nexpowder to Prevent Delayed Bleeding After Endoscopic Resection
Safety and effectiveness of a new hemostatic system to prevent delayed bleeding after endoscopic resection in a selected high-risk population (NEXPOWDER- ENDOHS).
- Trial name
- NEX-ENDOHS (NCT06096948)
- Testing
- NEXPOWDER-ENDOHS
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasme University Hospital
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT00153933
- Testing
- Bortezomib, CC-5013
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00217438
- Testing
- melphalan, amifostine trihydrate, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
The purpose of this study is to compare the effect of short-term (2 hours/120 minutes) and long-term (6 hours/360 minutes) schedules of crushed ice therapy (cryotherapy).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01653106
- Testing
- cryotherapy, questionnaire administration, pharmacological study
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Relapsed and Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Trial name
- NCT04155749
- Testing
- anitocabtagene-autoleucel
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients.
- Trial name
- rev/abraxane (NCT02075021)
- Testing
- Lenalidomide, nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.